Q2 2026 Ultragenyx Pharmaceutical Inc Earnings Call Transcript
Key Points
- Ultragenyx Pharmaceutical Inc (RARE) reported its highest quarterly revenue in company history at $214 million, with strong performance across all products including 50% growth for Evkeeza.
- The company reaffirmed its full-year revenue guidance, citing strong underlying demand and a rebound in orders in Q2.
- Two gene therapy launches (DTX401 for GSDIa and UX111 for Sanfilippo syndrome) are on track with PDUFA dates in August and September, representing first-ever treatments for these diseases.
- GTX-102 for Angelman syndrome is approaching a Phase 3 data readout in September/October, with a well-defined statistical plan and strong Phase 1/2 data showing durable benefits.
- The company has a clear path to profitability in 2027, supported by revenue growth, expense discipline, and potential monetization of priority review vouchers.
- Commercial infrastructure is highly leveraged, with 75% overlap in treatment centers for upcoming launches, and the team has experience from four prior product launches.
- Ultragenyx Pharmaceutical Inc (RARE) reported a net loss of $92 million for Q2 2026, with cash burn of $97 million in the quarter.
- The company faces uncertainty in the regulatory path for setrusumab (UX143) for osteogenesis imperfecta, as the MHRA indicated a new randomized study may be needed and the FDA requires further discussions on fracture analysis.
- The Phase 3 Aspire study for GTX-102 has a complex statistical design with alpha split between two endpoints, and there is risk of not meeting statistical significance on either.
- The company has not provided specific guidance on the impact of upcoming launches on profitability, and slower-than-expected ramping could affect the 2027 target.
- There is potential for placebo effects in the Angelman syndrome trial, particularly on the MDRI endpoint, which could dilute treatment effects.
- The company faces operational risks in managing two simultaneous BLA submissions and potential manufacturing inspections, which could delay approvals.
Good afternoon, and welcome to the Ultragenyx second-quarter 2026 financial results conference call. (Operator Instructions)
It is now my pleasure to turn the call over to Joshua Higa, Chief of Staff and Vice President of Investor Relations.
Thank you. We have issued a press release detailing our financial results, which you can find on our website at ultragenyx.com. Joining me on this call are Emil Kakkis, Chief Executive Officer and President; Howard Horn, Chief Financial Officer; Erik Harris, Chief Commercial Officer; and Eric Crombez, Chief Medical Officer.
I'd like to remind everyone that during today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. Please refer to the risk factors discussed in our latest SEC filings.
I'll now turn the call over to Emil.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
